Ann: SPP and Options Prospectus, page-2

LMELBOURNE, Australia, 24 August 2021: Dimerix Limited (ASX: DXB) (Dimerix or the Company), a clinical-stage biopharmaceutical company, announces that it has today lodged a prospectus (Prospectus) with the Australian Securities & Investments Commission. The Prospectus contains an offer of: a) new fully paid ordinary shares in the Company (Shares) under a share purchase plan (SPP) to existing shareholders with a registered address in Australia or New Zealand as at 7.00pm (AEST) on Friday, 13 August 2021 (Eligible Shareholders). The SPP provides each Eligible Shareholder with an opportunity to apply for up to $30,000 worth of new Shares at an issue price of $0.20 per Share, being the same price as the Placement as previously announced to the market on Monday, 16 August 2021; b) one free unlisted option for every two Shares issued under the SPP, exercisable at $0.40 and an expiry date of the earlier of 30 July 2024 or 20 Business Days after the Acceleration Trigger Date (SPP Option); c) one free unlisted option for every two Shares issued under the Placement, exercisable at $0.40 and an expiry date of the earlier of 30 July 2024 or 20 Business Days after the Acceleration Trigger Date (Placement Option), (together, the Offers) The Offers open today, Tuesday 24 August 2021 and are scheduled to close at 5.00pm on Tuesday, 28 September 2021. A copy of the Company's prospectus accompanies this announcement. For further information, please visit our website at www.dimerix.com or contact: Dr Nina Webster Dimerix Limited Chief Executive Officer & Managing Director Tel: +61 1300 813 321 E: [email protected] Follow us on LinkedIn and Twitter Rudi Michelson Monsoon Communications Tel: +61 3 9620 3333 Mob: +61 (0)411 402 737 E: [email protected]